Hypothesis Comparison

⚛ Collide these

Comparing 1 hypotheses side-by-side

|

Microglial xCT/SLC7A11 Selective Inhibition to Reduce Non-Cell-Autonomous Glutam

SLC7A11 · - · -
Composite
0.620
Price
$0.58
Evidence For
5
Evidence Against
5

System xC- (SLC7A11) is specifically expressed in microglia but not motor neurons, driving excessive glutamate release contributing to excitotoxicity. Selective xCT inhibitors could normalize microglial glutamate dynamics while preserving astrocyte cystine uptake for glutathione synthesis.

Radar Chart — 10 Dimensions

Score Comparison Bars

Mechanistic
0.70
Evidence
0.62
Novelty
0.55
Feasibility
0.42
Impact
0.62
Druggability
0.60
Safety
0.45
Competition
0.80
Data
0.68
Reproducible
0.65

Score Breakdown

DimensionMicroglial xCT/SLC7A11 Selecti
Mechanistic0.700
Evidence0.620
Novelty0.550
Feasibility0.420
Impact0.620
Druggability0.600
Safety0.450
Competition0.800
Data0.680
Reproducible0.650

Evidence

Microglial xCT/SLC7A11 Selective Inhibition to Reduce Non-Ce

Supporting Evidence
xCT expression is enriched in microglia compared to total spinal cord and absent from motor neurons PMID:25384799
During ALS disease progression, xCT levels increase in spinal cord and isolated microglia from SOD1 mice PMID:25384799
Microglial xCT deletion slows ALS symptoms in SOD1 mutant mice PMID:25384799
System xC- mediates BMAA-induced glutamate release and oxidative stress PMID:19374900
Non-cell-autonomous pathology represents validated ALS mechanism PMID:25384799
Contradicting Evidence
Sulfasalazine, an xCT inhibitor, reached clinical trials for ALS and did not emerge as standard-of-care - indicates lack PMID:25384799
Pharmacological inhibitors cannot achieve true cell-type selectivity - astrocytes require cystine uptake for glutathione PMID:FEASIBILITY_ASSESSMENT
Microglial heterogeneity oversimplified - xCT role may differ across activation states PMID:FEASIBILITY_ASSESSMENT

Debate Excerpts

Microglial xCT/SLC7A11 Selective Inhibition to Red

5 rounds · quality: 0.59

Theorist

Based on my comprehensive research gathering literature evidence and computational findings, I now present 6 novel therapeutic hypotheses for ferroptosis in ALS and motor neuron diseases. --- ## N...

Skeptic

# Critical Evaluation of Ferroptosis-Based Therapeutic Hypotheses for ALS ## Overview and Major Concerns Before evaluating individual hypotheses, several overarching issues must be addressed: **1...

Domain Expert

# Practical Feasibility Assessment: Ferroptosis-Based Therapeutic Hypotheses for ALS ## Executive Summary Of the seven hypotheses presented, **five survive critical evaluation with sufficient tran...

Synthesizer

{"ranked_hypotheses":[{"title":"GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade","description":"Small molecule mimetics of the GPX4 selenopeptide active site (Sec-γ-Glu-Cys-Gly) ...

Price History Overlay